The agency’s advisers cited concerns about the increased incidence of a rare but potentially serious blood clotting condition among those who received the company’s shot.
The C.D.C. recommends that other vaccines be preferred over J.&J.
The agency’s advisers cited concerns about the increased incidence of a rare but potentially serious blood clotting condition among those who received the company’s shot.
